Cabio Biotech Wuhan Co Ltd (688089) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.034x

Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.10 Million ≈ $8.21 Million USD) by net assets (CN¥1.64 Billion ≈ $239.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688089 net asset quality score to measure how much of total assets are equity-financed.

Cabio Biotech Wuhan Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Cabio Biotech Wuhan Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Cabio Biotech Wuhan Co Ltd to evaluate the quality of earnings relative to operating cash generation.

Cabio Biotech Wuhan Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
JVM Co. Ltd KQ:054950	0.035x
LongDa Construction & Development Corp TW:5519	0.062x
Boab Metals Ltd AU:BML	-0.020x
DUG Technology Ltd AU:DUG	0.167x
Virgin Galactic Holdings Inc NYSE:SPCE	-0.249x
Asian Energy Services Limited NSE:ASIANENE	-0.164x
Korea Asset In Trust Co Ltd KO:123890	-0.063x
ONWARD MEDICAL BV EO -12 F:63E	N/A

Annual Cash Flow Conversion Efficiency for Cabio Biotech Wuhan Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Cabio Biotech Wuhan Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see 688089 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.57 Billion ≈ $229.67 Million	CN¥173.04 Million ≈ $25.32 Million	0.110x	+139.09%
2023-12-31	CN¥1.49 Billion ≈ $218.60 Million	CN¥68.89 Million ≈ $10.08 Million	0.046x	-62.75%
2022-12-31	CN¥1.43 Billion ≈ $208.53 Million	CN¥176.40 Million ≈ $25.81 Million	0.124x	+65.60%
2021-12-31	CN¥1.38 Billion ≈ $202.20 Million	CN¥103.29 Million ≈ $15.11 Million	0.075x	-32.18%
2020-12-31	CN¥1.32 Billion ≈ $193.67 Million	CN¥145.88 Million ≈ $21.35 Million	0.110x	+4.38%
2019-12-31	CN¥1.25 Billion ≈ $182.85 Million	CN¥131.95 Million ≈ $19.31 Million	0.106x	-47.66%
2018-12-31	CN¥526.20 Million ≈ $77.00 Million	CN¥106.16 Million ≈ $15.53 Million	0.202x	-6.93%
2017-12-31	CN¥464.39 Million ≈ $67.96 Million	CN¥100.66 Million ≈ $14.73 Million	0.217x	+39.56%
2016-12-31	CN¥402.60 Million ≈ $58.91 Million	CN¥62.53 Million ≈ $9.15 Million	0.155x	+23.62%
2015-12-31	CN¥354.83 Million ≈ $51.92 Million	CN¥44.58 Million ≈ $6.52 Million	0.126x	+26.32%
2014-12-31	CN¥465.90 Million ≈ $68.18 Million	CN¥46.34 Million ≈ $6.78 Million	0.099x	+7.89%
2013-12-31	CN¥428.24 Million ≈ $62.66 Million	CN¥39.48 Million ≈ $5.78 Million	0.092x	--

About Cabio Biotech Wuhan Co Ltd

SHG:688089 China Biotechnology

Market Cap

$191.61 Million

CN¥1.31 Billion CNY

Market Cap Rank

#16715 Global

#4643 in China

Share Price

CN¥7.78

Change (1 day)

+2.23%

52-Week Range

CN¥6.98 - CN¥29.99

All Time High

CN¥48.06